Gamechanger

LinXis Biopharmaceuticals

Linxis Lab technician orange tube

LinXis Biopharmaceuticals

Facts

Mission:
It is our mission to develop technology that delivers medicines precisely to the cells where they are needed.

Fund: SME Fund

Contributes to transition:
Healthcare Transition (LSH)

Contributes to transition:
Healthcare Transition (LSH)

Contributes to SDG(s):

 

This is how LinXis technology works

Fibrosis occurs when excessive scar tissue forms in organs such as the liver, lungs, and kidneys. As a result, these organs function increasingly poorly. Existing medications can slow this process but not stop it. LinXis aims to change this with a technology that delivers medications specifically to the cells responsible for scar tissue formation. To this end, LinXis has developed so-called Fibrobodies. These are small proteins that can recognize the cells causing fibrosis. By linking these proteins to a tracer, LinXis can visualize the fibrosis-causing cells on scans. By linking these proteins to a medication, the drug can be delivered directly to the correct cells, while sparing healthy cells. With this technology, the company aims to detect and treat fibrosis more effectively.

Linxis Lab technician orange tube
“For millions of people, fibrosis is an insidious process that ultimately leads to organ failure. Aside from transplantation, doctors can still do too little about it. With this investment from our existing shareholders and ROM InWest, we are taking the step into the clinic. A successful first human study substantiates the value of our platform for applications in other organs and for collaborations with pharmaceutical partners.”
Bart Nijmeijer - LinXis
Bart Nijmeijer
CEO of LinXis Biopharmaceuticals

Investment ROM InWest

Investment manager Sara Schaafsma: “LinXis combines knowledge of targeted fibrosis treatment with the clinical expertise of Amsterdam UMC and the specialized medical imaging infrastructure in North Holland. This combination provides a strong foundation to further develop the technology and bring it to patients. With our investment, we support the translation of research into potential new treatments for a wide range of conditions in which fibrosis plays a central role.”

Healthcare Transition (LSH)

Innovating in Life Sciences and Health

Let you
Inspire

29 October 2026

LinXis raises nearly €5 million for first clinical study into fibrosis

News
The Amsterdam-based biotech company LinXis Biopharmaceuticals has raised nearly €5 million to use its innovative Fibrobody technology in patients for the first time...

Our
game changers

Our
game-
changers

Drystack has developed a circular and demountable dry-stack system for bricks. By replacing cement with a smart click system, Drystack 100% creates circular facades: demountable, reusable, and built in a...

Globally, around 40 million people live with severe blindness. Phosphoenix is developing a brain implant (neuroprosthetic system) that can restore functional vision using AI in people who later in life...

Greencovery has a sustainable solution to reuse residual streams from the food industry and convert them into valuable ingredients. In this way, a cost item, waste processing of residual materials, is transformed into an extra...

Phoenix Metals is an innovative company that recovers valuable raw materials from industrial waste streams such as steel slag, thereby playing an innovative role in the battery market.

Droppie was founded by Natascha Hermsen and Stef Traa and cleverly collects waste via special recycling shops, where consumers receive money for plastic packaging, textiles, cooking oil and...

Root Sustainability develops AI technology that allows retailers to make smart decisions based on product-specific data to concretely reduce the CO2 footprint in their supply chain. Dispersed data is quickly and efficiently...

Methotrexate is currently the most commonly prescribed basic drug for rheumatoid arthritis worldwide. Sixty to eighty per cent of patients receive this drug. The problem, however, is that methotrexate is too...

Thorizon is developing an innovative molten salt reactor that converts existing nuclear waste into clean, safe and efficient energy. Thanks to a patented system with interchangeable cartridges, the reactor makes best use of fuel and minimises...

Stay tuned

Subscribe to our newsletter and stay up to date with news, stories, relevant events and more.